New PET tracer could sharpen myeloma detection
NCT ID NCT03891914
First seen May 16, 2026 · Last updated Jun 21, 2026 · Updated 9 times
Summary
This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (18F-choline)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks. The goal is to find a more accurate, one-stop imaging method for diagnosis and treatment monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bordeaux University Hospital - Haut-Lévêque
Pessac, 33604, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-choline (a radioactive tracer used in PET/CT imaging)
What this could lead to
If successful, this could lead to a more accurate imaging test for multiple myeloma, potentially replacing the need for multiple scans.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The new tracer may not prove significantly better than the current standard.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.